Benzinga · Sep 11, 2026
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $30 price target.
CB
NASDAQ · CBLL
CeriBell, Inc. Common Stock
Healthcare · Medical - Devices
$25.04
Down-$0.54 (-2.16%)
Updated Sep 17, 2026, 1:54 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 757.49M
- P/E ratio
- -14.33
- Dividend yield
- 0.00%
- 52-week range
- $10.85 – $25.33
- Volume
- 323.52K
- Avg. volume
- 348.13K
Price performance
CBLL price history
1M range · 19 trading sessions · Daily adjusted prices
CBLL closed at $25.04 after 19 trading sessions, up 0.60% for the selected period.
- Last close
- $25.04
- Period change
- +0.60%
- Period low
- $23.37
- Period high
- $25.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $24.42 | $25.12 | $23.90 | $25.04 | 323.52K |
| Sep 14, 2026 | $23.65 | $24.61 | $23.645 | $24.33 | 280.71K |
| Sep 11, 2026 | $23.65 | $23.65 | $23.04 | $23.63 | 255.08K |
| Sep 10, 2026 | $24.13 | $24.29 | $23.11 | $23.43 | 220.13K |
| Sep 9, 2026 | $24.00 | $24.66 | $23.65 | $24.41 | 255.27K |
| Sep 8, 2026 | $24.33 | $24.66 | $23.84 | $24.31 | 297.33K |
| Sep 4, 2026 | $24.57 | $24.88 | $24.25 | $24.72 | 223.61K |
| Sep 3, 2026 | $24.99 | $24.99 | $24.08 | $24.57 | 331.93K |
| Sep 2, 2026 | $24.66 | $25.07 | $24.235 | $24.81 | 502.8K |
| Sep 1, 2026 | $23.82 | $24.66 | $23.68 | $24.58 | 325.98K |
| Aug 31, 2026 | $23.66 | $23.98 | $23.065 | $23.98 | 282.74K |
| Aug 28, 2026 | $23.40 | $23.76 | $23.32 | $23.73 | 245.94K |
| Aug 27, 2026 | $23.40 | $23.955 | $23.32 | $23.37 | 160.56K |
| Aug 26, 2026 | $23.65 | $23.76 | $22.97 | $23.45 | 225.75K |
| Aug 25, 2026 | $24.18 | $24.24 | $23.65 | $23.95 | 243.38K |
| Aug 24, 2026 | $23.95 | $24.33 | $23.65 | $23.94 | 408.94K |
| Aug 21, 2026 | $24.31 | $24.33 | $23.80 | $24.20 | 292.63K |
| Aug 20, 2026 | $24.76 | $24.98 | $24.15 | $24.31 | 262.28K |
| Aug 19, 2026 | $24.69 | $25.33 | $24.45 | $24.89 | 845.35K |
Latest CBLL news
The latest Smart Investors Daily articles mentioning CBLL.
Stock researchCompany · Overview
CBLL research
Overview
Company profile and research snapshot.
Company profile
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | BTIG | Buy | — |
| Aug 18, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | Canaccord Genuity | Buy | — |
| May 12, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 12, 2026
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CeriBell, Inc. (CBLL) 44th Annual J.P.
SeekingAlpha · Jan 12, 2026
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-12. The following slide deck was published by CeriBell, Inc.
globenewswire.com · Dec 9, 2025
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium screening and monitoring device.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
